The World Health Organization is hoping to drive down the cost of insulin by encouraging more generic drug makers to enter the market.
The organization hopes that by increasing competition for insulin, drug manufacturers will be forced to lower their prices.
Currently, only three companies dominate the world insulin market, Eli Lilly, Novo Nordisk and Sanofi. Over the past three decades they've worked to drastically increase the price of the drug, leading to an insulin availability crisis in some places.
In the United States, the price of insulin has increased from $35 a vial to $275 over the past two decades.